/TRXDW

TRXDW Stock - TransEnterix, Inc.

Q: What is the analyst price target for TRXDW?

Analyst price target information is not currently available for TRXDW.

Q: What is TRXDW's market cap?

Market capitalization information is not currently available for TRXDW.

Healthcare|Medical - Specialties|OTC

$0.15-11.76%

$0.02 (-11.76%) • Sep 18

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.17

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TRXDW

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.41

52W High$0.15

52W Low$0.15

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$8.58M	$7.09M	$8.23M	$3.17M	$8.53M
Gross Profit	$-5,031,000	$-3,785,000	$-2,864,000	$-1,991,000	$-12,200,000
Gross Margin	-58.7%	-53.4%	-34.8%	-62.7%	-143.0%
Operating Income	$-78,130,000	$-75,679,000	$-64,619,000	$-60,389,000	$-154,575,000
Net Income	$-78,433,000	$-75,561,000	$-62,462,000	$-59,312,000	$-154,201,000
Net Margin	-914.5%	-1066.2%	-758.8%	-1868.1%	-1807.5%
EPS	$-0.31	$-0.32	$-0.28	$-0.84	$-8.69

Company Overview

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Frequently Asked Questions about TRXDW

What is TRXDW's current stock price?

TransEnterix, Inc. (TRXDW) is currently trading at $0.15 per share. The stock has moved -11.76% today.

What is the analyst price target for TRXDW?

No analyst price targets are currently available for this stock.

What sector is TransEnterix, Inc. in?

TransEnterix, Inc. operates in the Healthcare sector, specifically within the Medical - Specialties industry. The company is traded on the OTC exchange.

What is TRXDW's market cap?

TransEnterix, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.

Does TRXDW pay dividends?

No, TransEnterix, Inc. does not currently pay a dividend to shareholders.